Navigation Links
Novel Vaccine Shows Promise against Early Stage Breast Cancer

A diagnosis of breast cancer has taken on a new meaning in the past 10 years, as research has produced a host of new therapies and detection techniques, significantly improving// long-term survival for women who have been fighting the disease. To build on these successes, researchers are now harnessing what they have learned about treating breast cancer and applying it to possible methods of prevention to reduce the total incidence of the disease. One study presented today at the American Association for Cancer Research’s Frontiers in Cancer Prevention Research meeting in Boston looks at a specific target in the fight against breast cancer and evaluates a potential vaccine that is yielding promising results for women who are at high-risk for the disease.

Targeted immunoediting of critical pathways responsible for breast cancer development: treatment of early breast cancer using HER-2/neu pulsed dendritic cells.

Multiple genetic targets have been discovered that may help fight breast cancer, including BRCA, estrogen receptors, and HER-2/neu, all of which have been known to predict the severity of disease, recurrence and overall survival. Developing novel therapies that target these specific genetic variances may be extremely beneficial in preventing breast cancer for many women.

In this study, researchers investigated a potential vaccine that targets HER-2/neu over-expression in early stage breast cancer, known as DCIS (ductal carcinomas in situ, or early stage cancer formation in the breast’s milk ducts). It is estimated at 50-60 percent of DCIS is directly related to HER-2/neu over-expression.

Patients with HER-2/neu overexpression were given a therapy of dendritic cells (DC, which work with the B- and T-cells to trigger immune responses) that were treated with HER-2/neu to evoke an immune response. The participants received four weekly vaccinations into normal lymph nodes in their groins and were evaluated both pre- and post-vaccination for immune response, level of HER-2/neu expression, and cell infiltrates.

The researchers found that most patients responded well to the vaccination. Nearly all patients (11 of 12) exhibited an initial immune response (shown by the presence of anti-HER-2/neu specific CD4+ T cells), and many of the patients developed protein antibodies to fight the HER-2/neu cells. Patients began to build up reserves of white blood cells following treatment and seemed to show long-term immune responses to HER-2/neu as a result of the therapy. Of the 12 study participants, six showed markedly reduced levels of HER-2/neu expression after the vaccination, and as a result, the investigators also noted an improvement in their severity of their disease.

“The results demonstrate for the first time that this DC vaccination may have significant clinical activity against certain types of breast cancer,” said Brian J. Czerniecki, M.D., of the University of Pennsylvania, and lead author of the study. “We are confident that targeted treatment with this vaccine may effectively fight not only DCIS, but may extend to prevention of breast cancer entirely.”

According to the American Cancer Society, approximately 200,000 women will be diagnosed with breast cancer in the U.S. in 2006, though thanks to new options for patients, about 20 percent, or 40,000 patients will die. Even with improved therapies, the chance of a woman having breast cancer at some time in her life is still about one in eight.

Source-NewswiseSRM
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: